Products
Product available for licensing
| Molecule Name | Strength | Therapy | Innovator & Brand | Registered Markets |
|---|---|---|---|---|
| Amlodipine Tablets | 5 mg and 10 mg | Antihypertensive | Istin ® | Approved in EU, UK Market |
| Cetirizine dihydrochloride Tablets | 10 mg | Antihistamines | Zirtek® | Approved in EU, UK Market |
| Levocetirizine dihydrochloride Tablets | 5 MG | Antihistamines | Xyzal® | Approved in EU, UK Market |
| Telmisartan Tablets | 20mg,40mg and 80mg | Angiotensin II receptor antagonists | Micardis® | Approved in EU, UK Market |
| Telmisartan/Amlodipine Tablets | 40mg/5mg 80mg/5mg 40mg/10mg 80mg/10mg |
Antihypertensive | Twynsta® | Approved in EU, UK Market |
| Paroxetin Tablets | 20 mg | Selective serotonin reuptake inhibitor (SSRI) | Seroxat® | Approved in EU, UK Market |
| Carbidopa and levodopa Tablets | 25 mg/100 mg 25 mg/250 mg 10 mg/100 mg12.5mg/50 mg |
Antiparkinsonian | Sinemet® | Approved in EU, UK Market |
Product available for licensing
| Molecule Name | Strength | Therapy | Innovator & Brand | Current Stage |
|---|---|---|---|---|
| Azithromycin Capsules | 250 mg | Antibiotics | Zithromax®(UK) | e CTD dossier is available for new filing. |
| Azithromycin Tablets | 250 mg and 500 mg | Antibiotics | Tromax®(UK) | e CTD dossier is available for new filing. |
| Raloxifene Tablets | 60 mg | Prevention of postmenopausal Osteoporosis | Evista® (Germany) |
e CTD dossier is available for new filing. |
| Telmisartan hydrochlorothiazide Tablets | 40 mg/12.5 mg 80 mg/12.5 mg 80 mg/25 mg |
Antihypertensive | Micardis plus® (Germany) | e CTD dossier is available for new filing. |
| Carbidopa and levodopa ER Tablets | 25 mg/100 mg 50 mg/200 mg |
Antiparkinsonian | Sinemet CR®(UK) | e CTD dossier is available for new filing. |
| Olmesartan medoxomil Tablets | 10 mg 20 mg 40 mg |
Angiotensin II receptor antagonists | Olmetec®(UK) | e CTD dossier is available for new filing |
| Olmesartan + Hydrochlorothiazide Tablets | 20 mg /12.5 mg 20 mg/25 mg 40 mg/12.5 mg 40 mg/25 mg |
Antihypertensive | CoOlmetec® (France) | e CTD dossier is available for new filing |
| Metformin IR Tablets | 500 mg 850 mg 1000 mg |
Type 2 Anti diabetics | Glucophage® (Spain) | e CTD dossier is available for new filing |
| Desloratadine Tablets | 5mg | Antihistamines | Aerius® (Belgium) | eCTD dossier is available for new filing |
| Etoricoxib Tablets | 60 mg 90 mg 120 mg |
NSAIDS | Arcoxia® (Netherland) | eCTD dossier is available for new filing |
DEVELOPMENT PIPELINE FOR EUROPE/UK
| Molecule Name | Strength | Therapy | Innovator & Brand | Current Stage |
|---|---|---|---|---|
| Dimethyl fumarate Capsules | 120 mg and 240 mg | Treatment of multiple sclerosis | Tecfidera®(Bulgaria) | BE Study scheduled in Q1 26 |
| Clopidogrel Tablets | 75 mg | Antiplatelet | Plavix®(France) | BE Study scheduled in Q1 26 |
| Hydroxyzine HCl Tablets | 10 mg and 25 mg | Antihistamine with anticholinergic | Atarax® (Germany) | PVB in Q2 2026 |
| Levocetirizine + montelukast Tablets | 5 mg /10 mg | Antihistamines | Montelukast-Singulair (Organon) & Levocetirizine –Zyzal (UCB) from Germany | PVB in Q2 2026 |
| Esomeprazole DR Tablets | 20 mg and 40 mg | Treatment of GERD | Nexium® (UK) | PVB in Q2 2026 |
| Rosuvastatin Tablets | 10 mg,20 mg and 40mg | Antihyperlipidemic | Crestor®(Germany) | e CTD dossier is available by March 26 |
| Escitalopram Oxalate Tablets | 5 mg ,10 and 20 mg | Antidepressants | Cipralex®(Denmark) | e CTD dossier is available by February 26 |
| Valsartan + hydrochlorothiazideTablets | 160 mg/12.5 mg | Antihypertensive | CoDiovan® (Denmark) |
e CTD dossier is available by March 26 |
| Valsartan + Amlodipine Tablets | 160 mg/10 mg | Antihypertensive | Exforge®(Denmark) | e CTD dossier is available by March 26 |
| Linagliptin Tablets | 5 mg | Type 2 antidiabetics | Tradjenta®(EU) | PVB in Q3 2026 |
| Linagliptin + Metformin HCl Tablets | 2.5 mg/500 mg 2.5 mg/850 mg 2.5 mg/1000 mg |
Type 2 antidiabetics | Jentadueto®(EU) | PVB in Q3 2026 |
| Dapagliflozin film coated Tablets | 5 mg and 10 mg | Type 2 antidiabetics | Forxiga® (EU) | PVB in Q3 2026 |
| Dapagliflozin + Metformin hydrochloride Tablets | 2.5 mg/1 gm. 5 mg/500 mg 5 mg/1 gm. 10 mg/500 mg 10 mg/1 gm. |
Type 2 antidiabetics | Xigduo XR® (EU) | PVB in Q3 2026 |
| Empagliflozin Tablets | 10 mg and 25 mg | Type 2 antidiabetics | Jardiance® (EU) | PVB in Q3 2026 |
| Empagliflozin + Metformin hydrochloride Tablets | 5 mg/500 mg 5 mg/1 mg 12.5 mg/500 mg 12.5 mg/1 gm. |
Type 2 antidiabetics | Synjardy® (EU) | PVB in Q3 2026 |